ADMA
ADMA Biologics Inc
NASDAQ: ADMA · HEALTHCARE · BIOTECHNOLOGY
$10.60
-2.75% today
Updated 2026-04-29
Market cap
$2.46B
P/E ratio
17.67
P/S ratio
4.83x
EPS (TTM)
$0.60
Dividend yield
—
52W range
$7 – $24
Volume
6.8M
WallStSmart proprietary scores
46
out of 100
Grade: C
Sell
Investment rating
6.7
Growth
B7.8
Quality
B+8.0
Profitability
A6.0
Valuation
B4/9
Piotroski F-Score
Moderate
3.6
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$20.67
+95.00%
12-Month target
$9.58
-9.62%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.62 — safe zone
+ Profit margin 28.80% — above average
+ ROE 35.60% — strong efficiency
+ Free cash flow $34.55M — positive
+ Revenue growth 15.90% QoQ
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $154.08M | $258.21M | $426.45M | $510.17M | $510.17M |
| Net income | $-65.90M | $-28.24M | $197.67M | $146.93M | $49.38M |
| EPS | — | — | — | — | $0.60 |
| Free cash flow | $-73.42M | $3.82M | $110.10M | $27.82M | $34.55M |
| Profit margin | -42.77% | -10.94% | 46.35% | 28.80% | 28.80% |
Peer comparison
Smart narrative
ADMA Biologics Inc trades at $10.60. representing a P/E of 17.67x trailing earnings. Our Smart Value Score of 46/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 3.62, it sits in the safe zone. TTM revenue stands at $510.17M. with profit margins at 28.80%.
Frequently asked questions
What is ADMA Biologics Inc's stock price?
ADMA Biologics Inc (ADMA) trades at $10.60.
Is ADMA Biologics Inc overvalued?
Smart Value Score 46/100 (Grade C, Sell).
What is the price target of ADMA Biologics Inc (ADMA)?
The analyst target price is $20.67, representing +95.0% upside from the current price of $10.60.
What is ADMA Biologics Inc's revenue?
TTM revenue is $510.17M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
3.62 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.83x
ROE35.60%
Beta0.82
50D MA$12.87
200D MA$15.95
Shares out0.23B
Float0.23B
Short ratio—
Avg volume6.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—